DEGROME THERAPEUTICS, INC.

Biotech · Private

Small-molecule degraders that recruit amyloid precursor protein (APP) to proteasomal and lysosomal degradation pathways for Alzheimer's disease treatment

Grants
$500K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of Small-Molecule Degraders of APP as the first-in-class drugs for Alzheimer's therapy$499,883
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1516Ideaya Biosciences, Inc.—$111M
1517Virscio Inc——
1518Moonwalk Biosciences—$110M
1519DEGROME THERAPEUTICS, INC.——
1520Bell Biosystems, Inc.—$2.4M
1521MOSAIC ENGINEERING LLC——
1522SHY THERAPEUTICS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.